Artificial Intelligence in Cancer Care and Clinical Trials

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.